Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
40 Erie Street, Suite 130, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 713 % -22.9%
Debt-to-equity 25.4 %
Return On Equity -54 % -23.1%
Return On Assets -43.1 % -18.4%
Operating Margin -923 % +35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 104M shares
Common Stock, Shares, Outstanding 102M shares +9.71%
Entity Public Float 1.92B USD -46.2%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 98.8M shares +11.4%
Weighted Average Number of Shares Outstanding, Diluted 98.8M shares +11.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 57.9M USD +59.6%
Research and Development Expense 466M USD +7.18%
General and Administrative Expense 126M USD +8.01%
Costs and Expenses 592M USD +7.36%
Operating Income (Loss) -534M USD -3.68%
Net Income (Loss) Attributable to Parent -519M USD -7.86%
Earnings Per Share, Basic -5.25 USD/shares +3.14%
Earnings Per Share, Diluted -5.25 USD/shares +3.14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 189M USD -16.6%
Marketable Securities, Current 412M USD -39.8%
Accounts Receivable, after Allowance for Credit Loss, Current 8.52M USD -76.6%
Assets, Current 640M USD -35.9%
Property, Plant and Equipment, Net 27.4M USD -16.4%
Operating Lease, Right-of-Use Asset 219M USD +90.1%
Assets 1.19B USD -8.45%
Accounts Payable, Current 14.6M USD +95.8%
Employee-related Liabilities, Current 24.1M USD -9.54%
Accrued Liabilities, Current 55.4M USD -17.4%
Contract with Customer, Liability, Current 20.7M USD -6.68%
Liabilities, Current 111M USD -3.78%
Contract with Customer, Liability, Noncurrent 18.3M USD -53%
Operating Lease, Liability, Noncurrent 190M USD +96.3%
Liabilities 319M USD +27.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 605K USD
Retained Earnings (Accumulated Deficit) -2.18B USD -31.3%
Stockholders' Equity Attributable to Parent 872M USD -17%
Liabilities and Equity 1.19B USD -8.45%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -121M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 60M USD +2601%
Net Cash Provided by (Used in) Investing Activities 5.9M USD
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 102M shares +9.71%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.8M USD +76.1%
Deferred Tax Assets, Valuation Allowance 783M USD +27.1%
Deferred Tax Assets, Gross 845M USD +30.2%
Operating Lease, Liability 210M USD +82.2%
Payments to Acquire Property, Plant, and Equipment 2.51M USD -34.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -518M USD -8.89%
Lessee, Operating Lease, Liability, to be Paid 295M USD +101%
Property, Plant and Equipment, Gross 77.1M USD +6.13%
Operating Lease, Liability, Current 20.2M USD +8.86%
Lessee, Operating Lease, Liability, to be Paid, Year Two 37.9M USD +46%
Lessee, Operating Lease, Liability, to be Paid, Year One 35.1M USD +33%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 84.6M USD +171%
Lessee, Operating Lease, Liability, to be Paid, Year Three 31.6M USD +25.9%
Deferred Tax Assets, Operating Loss Carryforwards 297M USD +14.7%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 26.7M USD +52.2%
Depreciation, Depletion and Amortization 2.51M USD +22.5%
Deferred Tax Assets, Net of Valuation Allowance 61.3M USD +89.2%
Share-based Payment Arrangement, Expense 154M USD +15.1%